Back to top
more

Patterson Companies (PDCO)

(Real Time Quote from BATS)

$20.11 USD

20.11
431,907

-0.65 (-3.13%)

Updated Nov 13, 2024 02:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Patterson Cos. (PDCO) Surpasses Q3 Earnings Estimates

Patterson Cos. (PDCO) delivered earnings and revenue surprises of 3.33% and 1.15%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

SmileDirectClub (SDC) Reports Q4 Loss, Lags Revenue Estimates

SmileDirectClub (SDC) delivered earnings and revenue surprises of 14.29% and 0.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Patterson Companies (PDCO) in Q3 Earnings?

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement at the Animal Health segment.

Reasons to Retain Patterson Companies (PDCO) Stock Now

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

West Pharmaceutical Services (WST) Q4 Earnings and Revenues Beat Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of 27.34% and 8.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.61% and 0.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Investors are optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Patterson Companies (PDCO) Q2 Earnings Beat, Sales Hurt by FX

Patterson Companies' (PDCO) fiscal second-quarter 2023 results reflect unfavorable currency movements.

Patterson Cos. (PDCO) Q2 Earnings Beat Estimates

Patterson Cos. (PDCO) delivered earnings and revenue surprises of 10.53% and 3.26%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Patterson Cos. (PDCO) Q2 Earnings Expected to Decline

Patterson Cos. (PDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Patterson Companies' (PDCO) New Buyout to Expand Product Suite

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Patterson Companies (PDCO) Inks Deal to Expand Product Suite

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its value-add platform.

ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -57.14% and 53.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Invacare (IVC) Reports Q3 Loss, Misses Revenue Estimates

Invacare (IVC) delivered earnings and revenue surprises of -45.95% and 13.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why Investors Should Hold Myriad Genetics (MYGN) Now

Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail

Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.

Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail

Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.

Company News for Sep 2, 2022

Companies in The News Are:CIEN,OLLI,SAIC,PDCO

Here's Why You Should Hold on to Chemed (CHE) Stock Now

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.

Medtronic (MDT) Obtains U.S. Distribution Rights for BioButton

Medtronic's (MDT) new deal with BioIntelliSense will ensure accessibility to BioButton for continuous vital sign measurements of general care patients in the United States.